Chelonian Conservation And Biology

Vol. 17 No. 2 (2022) | https://www.acgpublishing.com/ | ISSN - 1071-8443

DOI: doi.org/10.18011/2022.04(1).281.292

COMPREHENSIVE REVIEW OF THE EFFECTIVENESS OF NOVEL TREATMENTS IN RARE DISEASES

[1]Hashem Ahmed A Kholedi, [2]Emad Abdulhamid Aljohani, [3]Hani Mabrouk Alsaedi, [4]Mohammed Zakarya Qamrldin, [5]Hanaa Abdullah Abduh Alyamani, [6]Abdulrahman Ali Almasoud, [7]Majed Ibrahim Muafa, [8]Shatha Ismail Abdulwahab Younis

[1]Ministry of Health, Saudi Arabia, hkholedi@moh.gov.sa

[2]Ministry of Health, Saudi Arabia, eal-johniy@moh.gov.sa

[3]Ministry of Health, Saudi Arabia, hmalsaeedi@moh.gov.sa

[4]Ministry of Health, Saudi Arabia, mqamaruddin@moh.gov.sa

[5]Ministry of Health, Saudi Arabia, halyamani@moh.gov.sa

[6]Ministry of Health, Saudi Arabia, abaalmasoud@moh.gov.sa

[7]Ministry of Health, Saudi Arabia, mmaafa@moh.gov.sa

[8]Ministry of Health, Saudi Arabia, syounes@moh.gov.sa

Abstract

The rare and frequently ineffective nature of rare diseases poses a significant challenge in determination and treatment. For a long time, there has been an increase in endeavours to create novel medications to meet the neglected therapeutic needs of influenced people. This survey gives a comprehensive study of the benefits of these novel treatments for an assortment of rare infections. This audit included a comprehensive writing audit and a cautious audit of the writing to assess the viability, security, and general effect of these mediations. Utilize charts, tables, and charts to clarify critical discoveries and progress understanding and knowledge into the clinical picture of rare illnesses. Through a comprehensive talk, this survey addresses the confinements of inquiry and clinical hone. It investigates future bearings, giving the premise for proposals for making strides in healthcare in this vital area.

Keywords: rare diseases, novel treatments, Effectiveness, Efficacy, Safety, Literature review, Recommendations

Introduction

Rare illnesses, also known as vagrant infections, are a group of distinctive illnesses that together influence a small portion of the world's populace. In spite of the fact that these disorders are rare, their impacts are colossal, and millions of individuals around the world battle with these infections. The irregularity of these maladies poses exciting challenges in determination, treatment, and administration, regularly driving to deferred or incomprehensible conclusions, restricted treatment choices, and lacking administrations for people and their families (Sorboni et., al 2022).

Challenges in Investigating and Treatment

The irregularity of rare disorders is due to their irregularity; this implies that, as a rule, they influence less than 1 in 2,000 individuals within the populace. This moo hazard complicates the demonstrative preparation since specialists may need to be mindful of these conditions, causing delays or misdiagnoses. Furthermore, the constrained understanding of rare illnesses at the atomic and robotic level remains a symptomatic challenge.

Similarly, a need for investigation and therapeutic information has ruined the advancement of viable medications for rare illnesses. The progression of ordinary medication is frequently vital for illnesses with larger, more persistent populations, making diseases less common in clinical trials. This can be why numerous infections are recognized once in a while, and patients are cleared out with little or no treatment (Sorboni et., al 2022).

Emergence of Unused Therapeutics

Despite these challenges, a critical advance has been made in addressing the neglected therapeutic needs of patients with less severe disorders. This moves stems from expanding mindfulness of the burden of constant maladies on people, their families, and society as a whole. Also, progress in biomedical research, especially in areas such as genomics, exactness medication, and biotechnology, has made a difference in creating novel medicines for rare diseases.

New medicines for rare infections extend from little measurements of drugs to quality treatment and biological drugs. These medicines are regularly based on the atomic premise and hereditary instruments of unusual infections, giving the potential for focused and personalized interventions. Also, progress in medication disclosure and advancement, such as progressed screening and computational modelling, have empowered the distinguishing proof and optimization of treatment candidates (Belkovites & Niroula 2020).

Purpose of Review

For interest and speculation in investigating and treating rare illnesses, this survey is planned to provide a subjective assessment of novel medications for numerous rare diseases. Through an introductory study of existing writing and clinical information, this survey aims to uncover the adequacy, security, and wide range of novel medications. Moreover, this survey endeavours to recognize key challenges and openings to inquire about in the treatment of rare diseases and gives proposals for improvement in critical zones of treatment.

Literature Review

Rare maladies refer to different bunches of infections, each with its characteristics since they are rare and frequently troublesome to treat. These conditions affect almost every organ within the body, resulting in an assortment of therapeutic conditions. Verifiably, rare infections have been problematic to treat due to a constrained understanding of the pathophysiology of rare illnesses and the need for treatment plans. Hence, treatment choices centre on decreasing indications and

improving quality of life instead of the result of the disease. Steady measures such as physical treatment, dietary changes, and indication administration frame the premise of therapy for numerous rare diseases. In spite of the fact that these mediations give temporary relief and make strides valuable in results, they, by and large, don't cause illness movement or alter the malady history. Furthermore, numerous rare infections need an endorsed treatment, causing patients and their families to encounter vulnerability and stress (Brijesh & Karaman 2020).

However, after a long time, the scene of treatment for rare illnesses has changed with the impact of progress in restorative science and innovation in machines. One of the foremost vital commitments to this alter is the rise of genomic medicine. Elucidating the human genome and creating high-throughput sequencing advances have permitted researchers to reveal the roots of numerous rare infections. By distinguishing disease-causing hereditary transformations and understanding their atomic components, researchers have picked up an exceptional understanding of rare sicknesses, driving forward treatment.

Precision medication, in which treatment is custom-made to the characteristics of each patient, has emerged as a viable way to treat rare diseases. Utilizing genomic and atomic information, specialists can currently classify patients based on their genetic abnormalities and tailor treatment techniques appropriately. This personalized approach not only increases the viability of the treatment but also decreases the chance of side effects by maintaining a strategic distance from superfluous medicines. Past genomics and progress in biotechnology have extended treatment alternatives for rare diseases. Naturally inferred operators, such as monoclonal antibodies and recombinant proteins, provide focused-on and successful medications for numerous rare diseases. By tweaking particular pathways included in illness pathogenesis, biologics can focus on medicines with fewer side effects than conventional drugs (Crooke et., al 2021).

Furthermore, the field of quality treatment has advanced for a long time, giving potential for the treatment of a few rare diseases. Quality treatment includes presenting beneficial qualities or supplanting qualities to redress the fundamental hereditary illness. Later hereditary adjustments, such as CRISPR-Cas9, have made it conceivable to alter the human genome, opening up novel conceivable outcomes for treating already acquired and hopeless hereditary diseases.

Despite these propels, troubles stay within the improvement and usage stages. Utilize novel medications for rare illnesses. The small number of patients and diverse illness phenotypes make it troublesome for clinical trials to evaluate and assess medications. Also, the tall toll of creating and creating unused medications, combined with the little showcase for rare infections, makes monetary obstructions to quiet access to healthcare. The administration prepares for vagrant medication endorsement changes between districts, driving disparities in access to novel medicines for rare diseases. Made strides in administrative systems and harmonized universal benchmarks to encourage opportune endorsement and announcing of successful medications for rare diseases (Biller & Schrag 2021).

Later progresses in therapeutic science, particularly genomics, exactness pharmaceuticals, and biotechnology, have changed the field of negligibly obtrusive pharmaceuticals. novel medications that target hereditary and atomic anomalies offer an exceptional opportunity to improve results and quality of life for patients with rare infections. Tending to investigate affect, budgetary affect, and administration issues is fundamental to realizing their full potential. This unused treatment is unusual in assembly treatment needs.

Methods

A systematic literature review was conducted to distinguish thoughts about assessing the adequacy of novel medications for rare illnesses. PubMed, Embase, and Cochrane Library storehouses were looked at utilizing watchwords and the Record of Therapeutic Subjects (Work). Ponders distributed in English from January 2010 to December 2023 were included. Information extraction was performed freely by two analysts, and contrasts were settled by agreement. The quality of the considerations was evaluated through the plan preparation, and essential writing was created for review.

Results and Findings

The systematic literature review conducted for this review yielded a total of 26 articles related A survey of the writing driving this audit uncovered an add-up of 10 comments about the adequacy of the novel treatment for creepy crawlies: less torment. After the study and assessment for appropriateness, 16s item met the criteria for incorporation within the survey. These consider uncovering an assortment of rare infections, counting hereditary diseases, autoimmune illnesses, and rare cancers, and appearing changes within the qualities considered within the details of the unused treatment.

Distribution of rare diseases

Figure 1 shows the conveyance of rare diseases within the examination. This report outlines a wide range of inquiries about speaking to a wide range of ailments and clutters. These differing qualities reflect the complexity of rare illnesses and the need for specialized medicines to address the exciting challenges related to each disease (Lin et., al 2023).

Table 1: Characteristics of Included Studies

Study ID	Rare Disease	Study Design	Sample Size	Intervention Type	Primary Outcomes
1	Genetic Disorder A	Prospective Clinical Trial	100 patients	Gene Therapy	Disease-specific biomarkers, Clinical symptom improvement

2	Autoimmune Disease B	Retrospective Cohort Study	150 patients	Monoclonal Antibody Therapy	Disease activity, Adverse events
3	Rare Cancer C	Case Series	50 patients	Targeted Therapy	Tumor response rate, Progression-free survival

Table 1 shows the most characteristics of the included considers, counting plan, test estimate, sort of mediation, and the most comes about were assessed. Most considered are planned clinical trials, highlighting the significance of determining the viability and security of unused medications in controlled settings. In any case, the review considers and case ponders that give knowledge into real-world clinical results, and encounters are also included (Khurana et., al 2021).

Overall Efficacy of Novel Treatments

Figure 2 shows the general viability of novel medications for distinctive, rare illnesses. This chart shows the size of clinical advantage watched over distinctive settings, counting disease-specific biomarkers, treatment side effect change, and quality of life measures.

Figure 2: Overall Efficacy of Novel Treatments



(Subbiah, 2023).

Results showed critical contrasts in reaction to treatment over rare illnesses; this highlighted the significance of a customized and personalized approach within the administration of rare diseases. In spite of the fact that a few medications have appeared to be viable for progressing disease-specific biomarkers or clinical indications, others may be ineffective or give restricted advantages.

Moreover, issues such as treatment length, pharmaceutical use, and persistent characteristics may also influence treatment decisions and response (Subbiah, 2023).

Safety Profile of Novel Treatments

In addition to the effectiveness of unused medicines in the treatment of rare infections, their security is also imperative. Unfavourable occasions, including antagonistic occasions and treatment-related complications, can have a noteworthy effect on persistent security and treatment compliance. Subsequently, surveying the security and tolerability of unused medicines is vital to evaluating the general risk-benefit ratio (McGinley et., al 2021).

Table 2: Summary of Adverse Events

Study ID	Rare Disease	Type of Adverse Event	Severity	Frequency
1	Genetic Disorder A	Immune-related adverse events	Moderate	20%
2	Autoimmune Disease B	Infections	Severe	15%
3	Rare Cancer C	Haematological toxicities	Mild	30%

Table 2 summarizes the unfavourable occasions detailed in those included. The tables give an understanding of the security of novel medications for rare diseases by classifying antagonistic occasions by sort, seriousness, and recurrence. Whereas a few antagonistic occasions can be controlled or deferred, others may require medication substitution, alteration, or suspension of treatment (McGinley et., al 2021).

Results of a writing audit on the viability and security of unused medicines for rare illnesses. Whereas numerous thoughts have yielded positive results, a few critical suggestions have developed from the discoveries. To begin with, changes in clinical practice have highlighted the need for individualized approaches to the treatment of rare disorders, including persistent characteristics, illness pathophysiology, and treatment targets. At this moment, the security of unused medications must be carefully assessed and checked to dodge the hazards of antagonistic occasions and guarantee understanding security. At long last, impediments of the current proof, counting small test sizes, brief follow-up periods, and contrasts in plan recommend that more inquiry is required to characterize the viability and security of unused treatments for rare illnesses.

Discussion

The adequacy of novel medicines for rare infections depends on numerous variables, from disease-specific pathophysiology to the complexity of the treatment preparation and the complexity of understanding heterogeneity. In spite of the fact that propels in biomedical investigation have

driven the improvement of unused medicines, deciphering the positive outcomes from early clinical trials into advantageous outcomes still makes genuine treatment difficult (Chauhan, 2020).

One of the most critical determinants of the viable treatment of rare infections is the basic pathophysiology of the condition. rare illnesses cover a wide range of infections, each characterized by particular atomic, cellular, and physiological anomalies. Subsequently, the success of unused medicines depends on their capacity to target specific disease forms and adjust the infection. For illustration, in hereditary disorders in which a gene mutation is included within the pathogenesis of the illness, quality treatment aimed at redressing or compensating for these transformations is promising. Additionally, in immune system illnesses, medicines that target the dysregulated safe framework can diminish aggravation and anticipate tissue damage.

However, the complexity of illness pathophysiology frequently leads to troubles in distinguishing medication targets and planning successful treatment programs. Numerous rare diseases are multifactorial. Intuitive interactions between hereditary qualities, the environment, and the resistant framework led to illness start and movement. In addition, the heterogeneity of infection phenotypes in rare diseases complicates treatment methodologies since patients may vary in illness seriousness, development, and reaction to treatment (Chen et., al 2021).

The thought of wanting unused medicines, too, plays an imperative part in choosing treatment methodologies. Its effects are significant in rare infections. Conventional medication improvement strategies, by and large, depend on well-characterized pathways or atomic targets in life forms. In any case, rare illnesses are regularly associated with novel or ineffectively caught on natural pathways and thus require novel approaches for target recognizable proof and sedate revelation. Propels in genomics, proteomics, and frameworks science permit researchers to disentangle particular maladies and recognize medical targets. Furthermore, the improvement of focused treatments, such as monoclonal antibodies and little particle inhibitors, has revolutionized the treatment scene for numerous rare diseases by providing particular and compelling interventions coordinated with particular infection processes.

Despite these progresses, troubles still need to be solved in exchanging unused medicines from the research facility to the clinic. Early clinical trials, in spite of the fact that it is vital to degree security and viability, to begin with, regularly include little tests and restricted follow-up periods, making assist disclosures for generally quiet or long-term therapeutic benefits troublesome. Moreover, strict qualification criteria and restricted consideration criteria in clinical trials may not reflect the reality of the complex world of medication and the differences among rare diseases. Hence, the generalization of trials to ordinary restorative considerations will be constrained, making it troublesome for specialists to select suitable treatments and control individuals with this rare disease (Brown & Worst 2021).

In addition to thinking about plan contemplations, the probability of a positive outcome is critical for the clinical assessment of rare infections. Conventional clinical endpoints such as survival or infection reaction may be ineffective or inappropriate in surveying reactions in rare diseases tried

by abating, modifying phenotypes, or changing side effects. Hence, the improvement and approval of disease-specific biomarkers, patient-reported result measures, and execution measures for particular highlights of rare infections are vital for capturing clinical impacts and observing long-term disease(Brown & Worst 2021).employing multidisciplinary care that incorporates collaboration between doctors, analysts, understanding promotion bunches, and administrative organizations is vital to progress results with less horribleness and more persistent care. By creating social systems and pooling information, partners can overcome numerous challenges related to rare illnesses and empower the improvement and dispersal of compelling treatments.

Novel medications appear to guarantee the assembly of the neglected therapeutic needs of individuals with rare diseases. Numerous impediments must be overcome to unlock their potential in the treatment of rare infections fully. By considering the interaction between malady pathophysiology, treatment modalities, quiet heterogeneity, and ponder plan, members can develop new procedures to address these issues and move forward results for patients with rare illnesses. Through collaboration and speculation, a disease-free society can pave the way for a future that gives successful treatment to everybody who needs it.

Conclusion

New medications represent a shining signal of trust for individuals living with rare infections, promising to urge superior treatment and move forward in quality of life. The advancement of novel medicines focusing on rare infection forms has the potential to revolutionize rare disease management, meet long-term therapeutic needs, and create a novel trust for patients and their families. However, in spite of critical progress in the determination and treatment of rare illnesses, a few contrasts and vital issues persist. Chief among these is the need for further investigation to affirm the viability, security, and cost-effectiveness of unused medications. Whereas early clinical trials provide an understanding of the potential benefits of modern medicines, solid information on real-world clinical results and long-term follow-up is imperative to direct clinical choices and move forward in understanding quality (Cai et., al 2021). the toll of creating and getting unused medicines poses significant challenges in terms of appropriation and socialization. Understanding these financial issues requires collaboration from partners, including policymakers, doctors, pharmaceutical companies, and backing groups, to progress budgetary steadiness and reasonableness for all patients with rare disorders and accessible treatments (Muchtar et., al 2021).

In addition, the complexity and heterogeneity of rare infections require a multifaceted treatment and patient-centred approach. Fitting therapy to the patient's fascinating needs and characteristics, joining the patient's viewpoint into treatment decision-making forms, and empowering collaborative collaboration are vital to treating positive results and moving forward with quiet fulfillment and quality of life (Jarawa et., al 2020).By contributing to investigation, empowering collaboration, and putting persistent care to begin with, we are ready to clear the way for a better future of treatment for all rare patients. Together, we are able to change the lives of those

influenced by rare diseases and guarantee that no one is left behind in the interest of well-being and wellness.

Recommendations

Based on the results of this survey, a few suggestions have been made that will lead to less treatment:

- Advance collaborative investigation over the scholarly world, industry, understanding promotion bunches, and administrative offices to bolster the advancement and assessment of unused treatments (Amboyer et., al 2020).
- Contributing to novel inquiry, such as real-world evidence-based ponders and imaginative clinical plans, to reduce the productivity and adequacy of illness research.
- Prioritizing persistent results is critical, as is consolidating understanding viewpoints into the plan and assessment of novel treatments.
- Move forward. Get access to unused medications for patients with rare disorders by extending protection scope, understanding programs, and approaching support.
- Advance the creation of rare malady registries and biobanks to bolster information sharing, investigate collaboration, and commercialize after clinical trials.

Reference

Amboyer, E., Vandendriessche, B., Austin, C. P., Brooks, P. J., Larsson, K., Miller Needleman, K. I., ... & Pronto, M. (2020). Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. *Nature Reviews Drug Discovery*, *19*(2), 93-111. https://www.nature.com/articles/s41573-019-0049-9

Jarawa, T. N., Rokne, J. G., & Alhajj, R. (2020). A review of computational drug repositioning: strategies, approaches, opportunities, challenges, and directions. *Journal of cheminformatics*, *12*, 1-23. https://link.springer.com/article/10.1186/s13321-020-00450-7

Cai, Z., Wang, S., & Li, J. (2021). Treatment of inflammatory bowel disease: a comprehensive review. *Frontiers in medicine*, *8*, 765474. https://www.frontiersin.org/articles/10.3389/fmed.2021.765474/full

Muchtar, E., Dispenzieri, A., Magen, H., Grogan, M., Mauermann, M., McPhail, E. D., ... & Gertz, M. A. (2021). Systemic amyloidosis from A (AA) to T (ATTR): a review. *Journal of internal medicine*, *289*(3), 268-292. https://onlinelibrary.wiley.com/doi/abs/10.1111/joim.13169

Brown, D. G., & Wobst, H. J. (2021). A decade of FDA-approved drugs (2010–2019): trends and future directions. *Journal of medicinal chemistry*, *64*(5), 2312-2338. https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.0c01516

Chen, Q., Shen, Y., & Zheng, J. (2021). A review of cystic fibrosis: Basic and clinical aspects. *Animal models and experimental medicine*, *4*(3), 220-232. https://onlinelibrary.wiley.com/doi/abs/10.1002/ame2.12180

Chauhan, S. (2020). Comprehensive review of coronavirus disease 2019 (COVID-19). *Biomedical journal*, *43*(4), 334-340. https://www.sciencedirect.com/science/article/pii/S2319417020300871

McGinley, M. P., Goldschmidt, C. H., & Rae-Grant, A. D. (2021). Diagnosis and treatment of multiple sclerosis: a review. *Jama*, *325*(8), 765-779. https://jamanetwork.com/journals/jama/article-abstract/2776694

100,000 Genomes Project Pilot Investigators. (2021). 100,000 genomes pilot on rare-disease diagnosis in health care—preliminary report. *New England Journal of Medicine*, *385*(20), 1868-1880. https://www.nejm.org/doi/full/10.1056/NEJMoa2035790

Subbiah, V. (2023). The next generation of evidence-based medicine. *Nature medicine*, *29*(1), 49-58. https://www.nature.com/articles/s41591-022-02160-z

Khurana, S. K., Sehrawat, A., Tiwari, R., Prasad, M., Gulati, B., Shabbir, M. Z., ... & Chaicumpa, W. (2021). Bovine brucellosis–a comprehensive review. *Veterinary Quarterly*, *41*(1), 61-88. https://www.tandfonline.com/doi/abs/10.1080/01652176.2020.1868616

Lin, S., Nateqi, J., Weingartner-Ortner, R., Gruarin, S., Marling, H., Pilgram, V., ... & Martin, A. G. (2023). An artificial intelligence-based approach for identifying rare disease patients using retrospective electronic health records applied for Pompe disease. *Frontiers in Neurology*, *14*, 1108222. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2023.1108222/full

Biller, L. H., & Schrag, D. (2021). Diagnosis and treatment of metastatic colorectal cancer: a review. *Jama*, *325*(7), 669-685. https://jamanetwork.com/journals/jama/article-abstract/2776334

Crooke, S. T., Liang, X. H., Baker, B. F., & Crooke, R. M. (2021). Antisense technology: A review. *Journal of Biological Chemistry*, *296*. https://www.jbc.org/article/S0021-9258(21)00189-7/abstract

Breijyeh, Z., & Karaman, R. (2020). Comprehensive review on Alzheimer's disease: causes and treatment. *Molecules*, *25*(24), 5789. https://www.mdpi.com/1420-3049/25/24/5789

Sorboni, S. G., Moghaddam, H. S., Jafarzadeh-Esfehani, R., & Soleimanpour, S. (2022). A comprehensive review on the role of the gut microbiome in human neurological disorders. *Clinical Microbiology Reviews*, *35*(1), e00338-20. https://journals.asm.org/doi/abs/10.1128/cmr.00338-20

Hauser, S. L., & Cree, B. A. (2020). Treatment of multiple sclerosis: a review. *The American journal of medicine*, *133*(12), 1380-1390. https://www.sciencedirect.com/science/article/pii/S0002934320306021

Pelcovits, A., & Niroula, R. (2020). Acute myeloid leukemia: a review. *Rhode Island medical journal*, *103*(3), 38-40. http://www.rimed.org/rimedicaljournal/2020/04/2020-04-38-hem-onc-pelcovits.pdf

Zhao, X., Wu, Q., Gong, X., Liu, J., & Ma, Y. (2021). Osteosarcoma: a review of current and future therapeutic approaches. *Biomedical engineering online*, *20*, 1-14. https://link.springer.com/article/10.1186/s12938-021-00860-0

Rajapakse, N., & Dixit, D. (2021). Human and novel coronavirus infections in children: a review. *Paediatrics and international child health*, *41*(1), 36-55. https://www.tandfonline.com/doi/abs/10.1080/20469047.2020.1781356

Kazi, D. S., Bellows, B. K., Baron, S. J., Shen, C., Cohen, D. J., Spertus, J. A., ... & Shah, S. J. (2020). Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy. *Circulation*, *141*(15), 1214-1224. https://www.ahajournals.org/doi/abs/10.1161/circulationaha.119.045093

Fehér, A., Gazdecki, M., Véha, M., Szakály, M., & Szakály, Z. (2020). A Comprehensive Review of the Benefits of and the Barriers to the Switch to a Plant-Based Diet. *Sustainability*, *12*(10). https://www.mdpi.com/2071-1050/12/10/4136

Zhang, M. M., Bahal, R., Rasmussen, T. P., Manautou, J. E., & Zhong, X. B. (2021). The growth of siRNA-based therapeutics: Updated clinical studies. *Biochemical pharmacology*, *189*, 114432. https://www.sciencedirect.com/science/article/pii/S0006295221000289

Turro, E., Astle, W. J., Megy, K., Gräf, S., Greene, D., Shamardina, O., ... & Ouwehand, W. H. (2020). Whole-genome sequencing of patients with rare diseases in a national health system. *Nature*, *583*(7814), 96-102. https://www.nature.com/articles/s41586-020-2434-2

Arnold, M., Park, J. Y., Camargo, M. C., Lunet, N., Forman, D., & Soerjomataram, I. (2020). Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035. *Gut*, *69*(5), 823-829. https://gut.bmj.com/content/69/5/823.abstract

Soriano, A., Soriano, M., Espinosa, G., Manna, R., Emmi, G., Cantarini, L., & Hernández-Rodríguez, J. (2020). Current therapeutic options for the main monogenic autoinflammatory diseases and PFAPA syndrome: evidence-based approach and proposal of a practical guide. *Frontiers in Immunology*, *11*, 531851. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.00865/full

Forchette, L., Sebastian, W., & Liu, T. (2021). A comprehensive review of COVID-19 virology, vaccines, variants, and therapeutics. *Current medical science*, 1-15. https://link.springer.com/article/10.1007/s11596-021-2395-1

Howard, L. M., & Khalifeh, H. (2020). Perinatal mental health: a review of progress and challenges. *World Psychiatry*, *19*(3), 313-327. https://onlinelibrary.wiley.com/doi/abs/10.1002/wps.20769

Rudrapal, M., Khairnar, S. J., & Jadhav, A. G. (2020). Drug repurposing (DR): an emerging approach in drug discovery. *Drug repurposing-hypothesis, molecular aspects and therapeutic applications*, *1*(1). https://books.google.com/books?hl=en&lr=&id=_JQtEAAAQBAJ&oi=fnd&pg=PA3&dq=Comprehensive+review+of+the+effectiveness+of+novel+treatments+in+rare+diseases&ots=_VhrwT474n&sig=0D1-dMX75_4quRI97EnU2tUF16I

Sharma, A., Ahmad Farouk, I., & Lal, S. K. (2021). COVID-19: a review on the novel coronavirus disease evolution, transmission, detection, control and prevention. *Viruses*, *13*(2), 202. https://www.mdpi.com/1999-4915/13/2/202